Eisai Co Ltd

Read how Eisai’s subcutaneous Leqembi gained Chinese regulatory acceptance, unlocking a new Alzheimer’s market and boosting its portfolio.

Eisai Co., Ltd. is preparing to release its financial report, with analysts projecting a decline in earnings per share, but the company is also expecting robust revenue from its Alzheimer’s treatment, Leqembi.